Natural Interventions for Nonalcoholic Fatty Liver Disease

The Evidence Behind Natural Interventions for Non-alcoholic Fatty Liver Disease: Botanicals, Nutrients, and Probiotics for Treating This Common Ailment

Given the rise in non-alcoholic fatty liver disease (NAFLD) in both adults and pediatrics and the lack of an indicated pharmaceutical treatment,[1],[2] natural strategies for the treatment of this condition stand well-poised as the “next best thing.” Several nutritional supplements and botanicals have been studied clinically and show promise for treatment of NAFLD and its inflammatory counterpart, non-alcoholic steatohepatitis (NASH).[3] Given how many of these therapies address the factors that contribute to the development of NAFLD, it doesn’t take much reasoning to understand how they may effectively address some of the root causes of disease, rather than just addressing a symptom.

Five supplemental interventions with clinical or epidemiological evidence for their use in the setting of NAFLD are phosphatidyl choline, which provides phospholipids and choline, vitamin E, both as alpha tocopherols and a blend of delta and gamma tocotrienols, milk thistle seed extract, berberine, and probiotics.

Fatty Liver Changes: Correlated with a Phosphatidyl Choline Deficiency?

Phosphatidyl choline (PC) is essential to the health of all the cells in the body and is one of the main phospholipids of which cellular membranes are comprised.[4],[5] PC comprises over 90% of the total bile phospholipids content and facilitates fat emulsification, absorption, and transport.[6] Studies have shown that the recommended adequate intake (AI) of choline (see Table 1) may not be sufficient for prevention of symptoms of deficiency such as fatty liver changes or muscle damage.[7] Additionally, a recent study found that only 8% of US adults meet the recommended AI of choline, with vegetarians, postmenopausal women, and men at greatest risk of inadequacy.[8],[9] Genetic polymorphisms also may increase the need for choline,[10] which also is a source of methyl groups in the body.

In postmenopausal women with NAFLD, decreased choline intake has been shown to be significantly associated with an increased risk of fibrosis.[11] In animals, PC has been shown to protect against fibrosis associated with hepatic inflammation.[12],[13] Increased intake of PC has been shown to enhance biliary lipid secretion, thereby preventing cholestasis and subsequent liver damage via numerous mechanisms, including suppression of nuclear factor kappa B (NF-κB), a well understood molecular trigger of inflammation.[14],[15] In an animal model of biliary obstruction, supplemental PC has been shown to reduce liver damage, ductal proliferation, and fibrosis.[16]

PC is also essential for the health of the gut and is a primary component of the protective intestinal mucus layer.[17] In cell cultures, treatment with PC has been shown to reduce the migration of endotoxin through intestinal epithelial cells, further suppressing the associated inflammatory cytokine response.[18] PC also reduces endotoxin translocation in the setting of alcohol-induced increases in intestinal permeability.[19] This beneficial effect has been proposed as one of the mechanisms by which PC may be considered therapeutic in alcoholic liver disease.

Vitamin E

As an oxidative stress hit and diminished antioxidant defences has been proposed as a factor leading the development of NAFLD,[20] it should not be surprising that antioxidants have been investigated as a potential treatment for the condition.

Vitamin E has been studied in several clinical trials for the treatment of NAFLD, both as a standalone and adjunctive therapy. In a review of these studies, the dosage of vitamin E ranged from 400 to 1200 IU/day and study duration was from 24 weeks to more than two years.[21] Findings generally were positive, showing that when vitamin E was included, improvements in histology, steatosis, and/or transaminase levels were seen.[22],[23] In pediatrics with NAFLD, vitamin E has also been studied as a therapy. In an open-label pilot study including 11 children with NAFLD, supplementation of between 400 to 1200 IU of vitamin E for four to ten months was found to normalize transaminase and alkaline phosphatase levels during treatment, however they returned to abnormal once treatment was stopped.[24] Hepatic echogenicity did not change during the course of treatment.

Tocotrienols are the lesser-studied family of the naturally-occurring forms of vitamin E, with the tocopherols, more often found in nature, dominating scientific research.[25] However, tocotrienols are potent antioxidants, quoted in some research as having 40 to 60 times the antioxidant potential of tocopherols. Tocotrienols have been shown to improve total cholesterol and its fractions, reducing total and LDL cholesterol by 15 to 20%,[26],[27] and triglycerides up to almost 30%.[28] Tocotrienols have also been shown to have anti-inflammatory and antioxidant effects in vivo, lowering high-sensitivity C-reactive protein (hs-CRP) levels and reducing LDL oxidation.

Tocotrienols have also been studied as a treatment for NAFLD. In patients with ultrasound-diagnosed NAFLD, 200 mg of mixed tocotrienols (sourced from palm oil, with a high gamma fraction and an additional 61 mg of alpha tocopherols) taken twice daily for one year was shown to significantly normalize hepatic echogenic response and rate of remission compared to placebo.[29] In a second study, including patients with ultrasound-diagnosed NAFLD and transaminase elevation, 300 mg of tocotrienols (a 90:10 delta:gamma blend) taken twice daily for 12 weeks significantly decreased aspartate aminotransferase (AST), alanine aminotransferase (ALT), hs-CRP, and malondialdehyde (a marker of oxidative stress) levels as well as fatty liver index score compared to placebo.[30]

Milk Thistle

Milk thistle (Silybum marianum) is possibly the most well-known liver-protective botanical. Silymarin, a mixture of the active constituents of milk thistle, and silibinin, the most active compound found within it, have been shown in animal studies to reduce liver injury caused by acetaminophen, alcohol, iron overload, and radiation among other known liver-toxic substances.[31] Silymarin has been shown to increase levels of glutathione, a powerful antioxidant, in both the liver and intestines.[32] It also reduces lipid peroxidation, which damages cellular membranes, altering their function, and possibly causing cellular death.[33]

Silibinin and silymarin have been shown to activate a nuclear bile acid receptor known as farnesoid X receptor (FXR) in the liver, down-regulating inflammatory pathways and correcting insulin resistance and dyslipidemia induced by high-fat diet (HFD) feeding.[34] FXR is a key regulator of bile acid, glucose, and lipid balance in the body.[35] Medications which interact with FXR in a similar manner to these milk thistle derived compounds are also being investigated for the treatment of NAFLD and the related metabolic challenges.[36]

Clinical studies have also shown milk thistle improves various parameters associated with NAFLD. A 2017 meta-analysis found that treatment with milk thistle significantly reduces ALT and AST by −5.08 IU/L and −5.44 IU/L, respectively, in patients with NAFLD.[37] Dosages ranged from 140 mg once a day to 200 mg three times a day, for a duration of 8 to 24 weeks. At the lowest dosage of 140 mg daily, after 8 weeks, significant improvements were seen in fasting blood glucose (FBG), lipid profile, and serum insulin levels in addition to AST and ALT reductions from 56 to 37.77 IU/L and 78.73 to 53.05 IU/L, respectively.[38]


Berberine, the orangish-yellow alkaloid found in botanicals such as Oregon grape root and bark, goldenseal, and barberry, is another botanically-derived substance that has numerous mechanisms by which it may help protect against NAFLD and support its resolution.[39],[40],[41]

The antidiabetic and lipid-balancing effects of berberine have been demonstrated in several clinical trials,[42] and berberinemay be means via which berberine positively affects liver function. Berberine has been shown to alter metabolism-related gene expression and bile acid metabolism via pathways involving FXR as well.[43] In animal studies, berberine has been shown to have the effect of preventing HFD-associated obesity and hepatic triglyceride accumulation in wild-type (normal) mice, but not in those that had the genetic elimination of intestinal FXR expression. Berberine has also been shown to suppress obesity-associated inflammation and hepatic steatosis in mice by decreasing phosphorylation of the inflammatory complex known as JNK1,[44] a protein kinase implicated in the development of steatohepatitis.[45] JNK1 is strongly activated by environmental stressors and pro-inflammatory cytokines.

Berberine also acts in the gut. It affects not only the gut microbial balance,[46] but also directly influences intestinal permeability, improving tight junction integrity in animals subject to endotoxemia or cell cultures treated with pro-inflammatory cytokines.[47],[48]Direct anti-inflammatory effects have also been demonstrated.[49]

The benefits of berberine in NAFLD have also been demonstrated clinically in a randomized, parallel controlled, open-label clinical trial.[50] In patients with NAFLD, berberine was shown to restore normal hepatic architecture, lipid, and blood sugar metabolism, with significant improvements seen over the population who only implemented lifestyle changes.


Given the relationship between the many digestive system disturbances and liver enzyme elevation, it is not surprising that probiotics also have been studied as a treatment for NAFLD. A recent meta-analysis well summarizes the collective findings.[51]

One-hundred thirty-four patients diagnosed with NAFL/NASH by liver biopsy were included in this analysis, and each intervention used in the four randomized, controlled trials eligible for this meta-analysis was unique (Lactobacillus bulgaricus and Streptococcus thermophilus for three months; Lactobacillus GG for eight weeks; Bifidobacterium longum and fructooligosaccharides (FOS) for 24 weeks; and a proprietary combination of Lactobacillus plantarum, L. delbrueckii, L. acidophilus, L. rhamnosus, and Bifidobacterium bifidum for six months). The dosage of probiotics ranged from 500 million to 12 billion colony-forming units (CFUs) daily. The probiotic treatments were shown to significantly decrease ALT and AST levels by –23.71 UI/L and –19.77 UI/L, respectively. Significant improvements in total cholesterol, tumor necrosis factor (TNF)-α levels, and insulin resistance were also noted.

Two additional clinical trials investigated probiotics as a treatment for pediatric NAFLD. In a double-blind, placebo-controlled, pilot study, twelve children, having an average age of 10.7 years old, with ultrasound-diagnosed fatty liver changes and persistent transaminase elevation were given 12 billion CFUs of L. rhamnosus GG or placebo daily for 8 weeks. Treatment with the probiotic significantly reduced ALT levels compared to placebo, however liver echogenicity and AST levels did not change. Additionally, anti-peptidoglycan-polysaccharide antibodies, an indicator of bacteria or bacterial membrane translocation through the intestinal barrier, significantly decreased in children receiving the probiotic compared to placebo.[52] The second study investigated treatment of children having biopsy-proven NAFLD with VSL #3, a high potency blend of 8 probiotic strains (including Streptococcus thermophilus, 3 Bifidobacteria spp., and 4 Lactobacillus spp.), compared to placebo.[53] In children receiving the probiotic, fatty liver scores were significantly improved with the probability of none, light, moderate, or severe fatty liver at the end of the study being 21%, 70%, 9% and 0% compared to 0%, 7%, 76% and 17% in the placebo group.


There is a wide range of safe and effective options available that support the restoration of health in those with NAFLD. Although each individual may have different underlying mechanisms contributing to hepatic dysfunction and inflammatory changes, each of these supportive natural agents—and many others (see Table 2)—may support normal liver function in individuals with these challenges.


Table 2: Nutritional and botanical interventions for NAFLD. Nutrients such as these should be used under the guidance of a qualified and licensed healthcare practitioner.

Nutrient Dosage Mechanism
Phosphatidylcholine (PC), a source of dietary choline 1.5 g twice daily with meals (PC) OR 200 mg twice daily (choline) Choline is a common dietary deficiency. PC is necessary for production of bile and protective gastrointestinal mucosa barrier.
Milk thistle seed 140 to 200 mg once to three times daily Hepatoprotective. Supports hepatic glutathione levels, stabilizes bile salt export pump (BSEP), and activates FXR pathways.
Berberine HCl 500 mg two to three times daily[54] Improves serum glucose and lipid profiles, also reducing hepatic fat content.
Probiotics, including strains such as B. longum, B. bifidum, S. thermophilus, L. rhamnosus, L. acidophilus, and L. plantarum 12 billion colony-forming units (CFUs) daily Improved gut epithelial barrier function and reduced intestinal and systemic inflammation.[55]
Acetyl-glutathione 300 mg daily[56] Improves detoxifying ability of hepatocytes.[57]
N-acetylcysteine (NAC) 500–600 mg twice daily, best taken on an empty stomach NAC blocks the propagation of lipid peroxidation and supports hepatic glutathione levels.[58]
Vitamin E (tocopherols)



400 to 1200 IU daily with food

200 to 300 mg twice daily with food

Protective antioxidant.

Tocotrienols attenuate triglyceride accumulation by regulating fatty acid synthase and carnitine palmitoyltransferase enzymes, leading to a reduction of hepatic inflammation and endoplasmic reticulum stress.[59]

Omega-3 essential fatty acids 2 – 4 g daily, with meals


Omega-3 polyunsaturated fatty acids are known to downregulate sterol regulatory element-binding protein-1c and upregulate peroxisome proliferator-activated receptor alpha, thus favoring fatty acid oxidation and reducing steatosis.[60]

Dr. Carrie Decker, ND graduated with honors from the National College of Natural Medicine (now the National University of Natural Medicine) in Portland, Oregon. Dr. Decker sees patients remotely, with a focus on gastrointestinal disease, mood imbalances, eating disorders, autoimmune disease, and chronic fatigue. Prior to becoming a naturopathic physician, Dr. Decker was an engineer, and obtained graduate degrees in biomedical and mechanical engineering from the University of Wisconsin-Madison and University of Illinois at Urbana-Champaign respectively. Dr. Decker continues to enjoy academic research and writing and uses these skills to support integrative medicine education as a writer and contributor to various resources. Dr. Decker supports Allergy Research Group as a member of their education and product development team.
[1] Spengler EK, Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clinic Proceedings. 2015;90(9):1233–1246.
[2] Berardis S, Sokal E. Pediatric non-alcoholic fatty liver disease: an increasing public health issue. Eur J Pediatr. 2014 Feb;173(2):131-9.
[3] Jadeja R, et al. Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects. Evid Based Complement Alternat Med. 2014:648308.
[4] Pomorski T, et al. Lipid distribution and transport across cellular membranes. Semin Cell Dev Biol. 2001 Apr;12(2):139-48.
[5] Yamaji-Hasegawa A, et al. Asymmetric distribution of phospholipids in biomembranes. Biol Pharm Bull. 2006 Aug;29(8):1547-53.
[6] Hişmioğullari AA, et al. Biliary lipid secretion. Turk J Gastroenterol. 2007 Jun;18(2):65-70.
[7] Fischer LM, et al. Sex and menopausal status influence human dietary requirements for the nutrient choline. Am J Clin Nutr. 2007 May;85(5):1275-85.
[8] Wallace TC, et al. Usual Choline Intakes Are Associated with Egg and Protein Food Consumption in the United States. Nutrients. 2017 Aug 5;9(8).
[9] Zeisel SH. Gene response elements, genetic polymorphisms and epigenetics influence the human dietary requirement for choline. IUBMB Life. 2007 Jun;59(6):380-7.
[10] Zeisel SH. Gene response elements, genetic polymorphisms and epigenetics influence the human dietary requirement for choline. IUBMB Life. 2007 Jun;59(6):380-7.
[11] Guerrerio AL, et al. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr. 2012 Apr;95(4):892-900.
[12] Ma X, et al. Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J Hepatol. 1996 May;24(5):604-13.
[13] Lieber CS, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology. 1994 Jan;106(1):152-9.
[14] Chanussot F, et al. Prevention by dietary (n-6) polyunsaturated phosphatidylcholines of intrahepatic cholestasis induced by cyclosporine A in animals. Life Sci. 2003 Jun 13;73(4):381-92.
[15] Karaman A, et al. Protective effect of polyunsaturated phosphatidylcholine on liver damage induced by biliary obstruction in rats. J Pediatr Surg. 2003 Sep;38(9):1341-7.
[16] Karaman A, et al. Protective effect of polyunsaturated phosphatidylcholine on liver damage induced by biliary obstruction in rats. J Pediatr Surg. 2003 Sep;38(9):1341-7.
[17] Stremmel W, et al. Mucosal protection by phosphatidylcholine. Dig Dis. 2012;30 Suppl 3:85-91.
[18] Parlesak A, et al. Conjugated primary bile salts reduce permeability of endotoxin through intestinal epithelial cells and synergize with phosphatidylcholine in suppression of inflammatory cytokine production. Crit Care Med. 2007 Oct;35(10):2367-74.
[19] Mitzscherling K, et al. Phosphatidylcholine reverses ethanol-induced increase in transepithelial endotoxin permeability and abolishes transepithelial leukocyte activation. Alcohol Clin Exp Res. 2009 Mar;33(3):557-62.
[20] Buzzetti E, et al. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016 Aug;65(8):1038-48.
[21] El Hadi H, et al. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? Antioxidants (Basel). 2018 Jan 16;7(1).
[22] Bugianesi E, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005 May;100(5):1082-90.
[23] Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010 May 6;362(18):1675-85.
[24] Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000 Jun;136(6):734-8.
[25] Peh HY, et al. Vitamin E therapy beyond cancer: Tocopherol versus tocotrienol. Pharmacol Ther. 2016 Jun;162:152-69.
[26] Qureshi AA, et al. Dose-dependent modulation of lipid parameters, cytokines, and RNA by delta-tocotrienol in hypercholesterolemic subjects restricted to AHA Step-1 diet. Brit J of Med & Med Res. 2015;6(4):351-66.
[27] Qureshi AA, et al. Impact of delta-tocotrienol on inflammatory biomarkers and oxidative stress in hypercholesterolemic subjects. Clin Exp Cardiology. 2015;6(4):1000367.
[28] Zaiden N, et al. Gamma delta tocotrienols reduce hepatic triglyceride synthesis and VLDL secretion. J Atheroscler Thromb. 2010 Oct 27;17(10):1019-32.
[29] Magosso E, et al. Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial. Nutr J. 2013 Dec 27;12(1):166.
[30] Pervez MA, et al. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease. Turk J Gastroenterol. 2018 Mar;29(2):170-176.
[31] Abenavoli L, et al. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010 Oct;24(10):1423-32.
[32] Valenzuela A, et al. Selectivity of silymarin on the increase of the GSH content in different tissues of the rat. Planta Med. 1989 Oct;55(5):420-2.
[33] Rui YC. Advances in pharmacological studies of silymarin. Mem Inst Oswaldo Cruz. 1991;86 Suppl 2:79-85.
[34] Gu M, et al. Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor. Front Pharmacol. 2016 Sep 28;7:345.
[35] Ali AH, et al. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015 Jan;3(1):5.
[36] Traussnigg S, et al. Efficacy and safety of the non-steroidal farnesoid X receptor agonist PX-104 in patients with non-alcoholic fatty liver disease (NAFLD). Zeitschrift für Gastroenterologie. 2017 May;55(05):A71.
[37] Zhong S, et al. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials. Medicine (Baltimore). 2017 Dec;96(49):e9061.
[38] Hajiaghamohammadi AA, et al. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. Hepat Mon. 2012 Aug;12(8):e6099.
[39] Birdsall TC, et al. Berberine: therapeutic potential of an alkaloid found in several medicinal plants. Altern Med Rev. 1997;2:94-103.
[40] Imanshahidi M, et al. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, Berberine. Phytother Res. 2008 Aug;22(8):999-1012.
[41] Zhu X, et al. The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease. Molecules. 2016 Oct 14;21(10).
[42] Lan J, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015 Feb 23;161:69-81.
[43] Sun R, et al. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. Mol Pharmacol. 2017 Feb;91(2):110-122.
[44] Guo T, et al. Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity. Sci Rep. 2016 Mar 3;6:22612.
[45] Schattenberg JM, et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology. 2006 Jan;43(1):163-72.
[46] Han J, et al. Modulating gut microbiota as an anti-diabetic mechanism of berberine. Med Sci Monit. 2011;17:RA164-7.
[47] Gu L, et al. Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. J Infect Dis. 2011 Jun 1;203(11):1602-12.
[48] Li N, et al. Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells. Eur J Pharm Sci. 2010 Apr 16;40(1):1-8.
[49] Ma X, et al. The Pathogenesis of Diabetes Mellitus by Oxidative Stress and Inflammation: Its Inhibition by Berberine. Front Pharmacol. 2018 Jul 27;9:782.
[50] Yan HM, et al. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS One. 2015 Aug 7;10(8):e0134172.
[51] Ma YY, et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013 Oct 28;19(40):6911-8.
[52] Vajro P, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011 Jun;52(6):740-3.
[53] Alisi A, et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014 Jun;39(11):1276-85.
[54] Pérez-Rubio KG, et al. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2013 Oct;11(5):366-9.
[55] Iacono A, et al. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011 Aug;22(8):699-711.
[56] Honda Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterol. 2017 Aug 8;17(1):96.
[57] Dentico P, et al. [Glutathione in the treatment of chronic fatty liver diseases]. Recenti Prog Med. 1995 Jul-Aug;86(7-8):290-3.
[58] Khoshbaten M, et al. N-acetyl-cysteine improves liver function in patients with non-alcoholic fatty liver disease. Hepatitis Mon. 2010;10(1):12-16.
[59] Muto C, et al. Gamma-tocotrienol reduces the triacylglycerol level in rat primary hepatocytes through regulation of fatty acid metabolism. J Clin Biochem Nutr. 2013;52(1):32-37.
[60] Parker HM, et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;56(4):944-51.